3,148 Shares in AbbVie Inc. $ABBV Purchased by Cambria Investment Management L.P.

Cambria Investment Management L.P. purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 3,148 shares of the company’s stock, valued at approximately $729,000.

A number of other large investors have also added to or reduced their stakes in the company. Evolution Wealth Management Inc. purchased a new stake in AbbVie during the second quarter valued at $26,000. Chelsea Counsel Co. purchased a new position in shares of AbbVie in the 3rd quarter worth $26,000. Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie in the 3rd quarter worth $31,000. Caitlin John LLC bought a new stake in shares of AbbVie in the 3rd quarter worth about $33,000. Finally, Delos Wealth Advisors LLC purchased a new stake in shares of AbbVie during the 2nd quarter valued at about $39,000. Institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on ABBV shares. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Evercore reduced their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie signed a multi‑year collaboration with Alloy Therapeutics to develop a next‑generation antibody discovery platform aimed at hard‑to‑drug immunology targets — a pipeline boost that could support future biologics and reduce reliance on existing blockbusters. Is AbbVie (ABBV) Quietly Rewiring Its Immunology Edge With Alloy’s Antibody Discovery Deal?
• Positive Sentiment: Allergan Aesthetics (an AbbVie company) released global consumer research and is rolling out updated educational and treatment frameworks, reinforcing revenue diversification in aesthetic products and services. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: The U.S. FDA asked manufacturers of certain Parkinson’s drugs to add seizure‑risk warnings — a classwide safety advisory that may affect companies with Parkinson’s portfolios; AbbVie’s direct exposure is unclear but investors should monitor any label updates. US FDA flags seizure risk with certain Parkinson’s drugs, seeks label warnings
• Neutral Sentiment: Macro/flow note — commentary about defensive ETFs and rotation into dividend/defensive sectors could support demand for large dividend payers like AbbVie, but it’s not a catalyst unique to the company. The Market’s Favorite Active ETF Was Made for This Moment. Is It Delivering?
• Negative Sentiment: Johnson & Johnson’s FDA approval of Icotyde, a once‑daily oral IL‑23 inhibitor, materially raised competitive concerns for AbbVie’s Skyrizi (an injectable IL‑23 product). The market reacted sharply as an oral pill can take share from injectables, driving recent ABBV weakness. ABBV Stock Slides 5%: Is J&J’s Icotyde a Threat to Skyrizi?
• Negative Sentiment: A generic entrant (Milnacipran HCl) for Savella® was launched, signaling ongoing generic pressure on some of AbbVie’s older products and modest revenue risk in pain management categories. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®
• Negative Sentiment: Short‑term price action: analysts and market pieces highlight a recent pullback and underperformance vs. peers, amplifying volatility as investors re‑price growth assumptions for Skyrizi and the company’s near‑term outlook. AbbVie (ABBV) Declines More Than Market: Some Information for Investors

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by company insiders.

AbbVie Price Performance

AbbVie stock opened at $204.34 on Friday. The stock has a market capitalization of $361.31 billion, a PE ratio of 86.59, a price-to-earnings-growth ratio of 0.72 and a beta of 0.34. The business has a 50 day simple moving average of $223.09 and a 200-day simple moving average of $224.67. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the firm posted $2.16 EPS. The business’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.